Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close. Management will host a conference call and webcast the same day at 5:00 PM ET to discuss results and provide a business update.
A live Q&A follows the presentation. A replay of the webcast will be available for a limited time on Kyntra Bio’s Events & Presentations page. Phone access requires registration to receive dial-in details.
Details
News Market Reaction – KYNB
On Mar 9, the day this news came out, KYNB closed 7.31% above the previous close.
Data tracked by StockTitan Argus for the Mar 9 session.
Key Figures
- Results period
- Fourth quarter and full year 2025
- Scope of upcoming financial results
- Earnings date
- March 16, 2026
- Scheduled release after market close
- Conference call time
- 5:00 PM Eastern Time
- Start time of earnings call
Historical Context
-
Positive Phase 1b/2 data for FG-3246 combo in mCRPC patients.
-
Participation in Oppenheimer and Leerink healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.